Manchester, 6th May 2009 DxS Ltd, a personalised medicine company and leaders in the provision of companion diagnostics, has today announced the promotion of, and the appointment of Jeff Devlin, Chief Operating Officer, to the board of DxS and Peter Collins to Senior Vice President of Business Development.
Jeff Devlin, Chief Operating Officer, has joined the DxS Executive Board after his appointment in January of this year. Prior to DxS, Jeff held positions as Executive VP and Executive Committee member of Shire Pharmaceuticals, where he played a key role in strategy and integration. Before this he was a Partner in Ernst and Young’s life science division.
Peter Collins has over 25 years experience in the diagnostics industry, specifically companion diagnostics in the targeted oncology market. Mr. Collins has held senior executive roles at a number of early stage diagnostic and life science companies including Vysis Europe (Abbott Molecular Diagnostics), Quantase (Bio-Rad Laboratories), Gentronix, Biogenex and Pronostics.
Dr. Stephen Little, CEO of DxS, said: “We are delighted to be able to promote Jeff and Peter to more senior positions within the company. Both have contributed significantly to our vision of becoming one of the leaders in the personalised medicine space.”
Despite the economic downturn, DxS continues to expand. The last twelve months has seen the company’s workforce more than double in size with new manufacturing space taken at their Manchester site and a global distribution deal agreed with Roche Molecular Diagnostics for the TheraScreen® diagnostic kits.
DxS is a personalised medicine company providing molecular diagnostics to aid doctors and drug companies in selecting therapies for patients. Working in partnership with pharmaceutical companies to support the development and sales of targeted cancer therapies by providing biomarkers and companion diagnostics.
DxS has a continually expanding portfolio of cancer mutation products. The TheraScreen® range of CE-marked clinical diagnostic kits can identify genetic tumour mutations that affect how patients respond to cancer therapies, thus enabling doctors to provide the most beneficial treatment. DxS produce two clinical diagnostic kits, K-RAS and EGFR-29.
The TheraScreen: K-RAS Mutation kit is a companion diagnostic for Vectibix® (Amgen) and Erbitux® (Merck KGaA) for the treatment of colorectal cancer. DxS has an exclusive global distribution agreement with Roche Diagnostics for the distribution of the TheraScreen: K-RAS and TheraScreen: EGFR29 Mutation kits.
DxS’ pioneering real-time PCR technology Scorpions® is highly regarded for its proven speed and sensitivity, and is combined with ARMS (allele specific PCR) to develop each unique DxS product. This class-leading technology is also available for licence to diagnostic companies, for research, or for other varied applications.
DxS is a private, venture capital-backed company operating from the heart of Manchester’s Technology Quarter in the UK.
For further information please visit www.dxsdiagnostics.com.
